We previously demonstrated the anti-metastatic effect of pharmacological inhibitors targeting the SRPK1/2 family in melanoma (Gammons et al., 2014; Moreira et al., 2018; Moreira et al., 2022). Here, SRPK1 is linked to melanoma.